A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study

Huaqing Shi1, Zhou Chen1, Shi Dong1, Ru He1, Yan Du1, Zishun Qin3 and Wence Zhou1,2*

Abstract

Objective: Pancreatic body tail carcinoma (PBTC) is a relatively few pancreatic cancer in clinical practice, and its specific clinicopathological features and prognosis have not been fully described. In this study, we aimed to create a nomogram to predict the overall survival (OS) of patients with advanced PBTC.

Methods: We extracted clinical and related prognostic data of advanced PBTC patients from 2000 to 2018 from the Surveillance, Epidemiology, and End Results database. Independent prognostic factors were selected using univariate and multivariate Cox analyses, and a nomogram was constructed using R software. The C-index, area under the curve (AUC) of receiver operating characteristic curves, calibration curves, and decision curve analysis (DCA) were used to assess the clinical utility of the nomogram. Finally, OS was assessed using the Kaplan–Meier method.

Results: A total of 1256 patients with advanced PBTC were eventually included in this study. Age, grade, N stage, M stage, surgery, and chemotherapy were identified as independent risk factors using univariate and multivariate Cox regression analyses (p < 0.05). In the training cohort, the calibration index of the nomogram was 0.709, while the AUC values of the nomogram, age, grade, N stage, M stage, surgery, and chemotherapy were 0.777, 0.562, 0.621, 0.5, 0.576, 0.632, and 0.323, respectively. Meanwhile, in the validation cohort, the AUC values of the nomogram, age, grade, N stage, M stage, surgery, and chemotherapy were 0.772, 0.551, 0.629, 0.534, 0.577, 0.606, and 0.639, respectively. Good agreement of the model in the training and validation cohorts was demonstrated in the calibration and DCA curves. Univariate survival analysis showed a statistically significant effect of age, grade, M stage, and surgery on prognosis (p < 0.05).

Conclusion: Age, grade, M stage, and surgery were independently associated with OS, and the established nomogram was a visual tool to effectively predict OS in advanced PBTC patients.

Keywords: Nomogram, Pancreatic body tail cancer, Prognosis, Overall survival, SEER database

Introduction

Pancreatic cancer is a highly malignant solid tumour of the digestive organs with a poor prognosis, of which pancreatic adenocarcinoma (PAAD) of the pancreatic duct accounts for more than 90% of pancreatic cancers [1]. Approximately 80% of PAAD patients have locally advanced or distant metastases at the time of presentation and are lost to surgery [2]. Pancreatic cancer is the fourth leading cause of cancer death [3], with a 5-year survival rate of less than 5% [3], of which only 15–20% of patients with PAAD are diagnosed at the surgically resectable stage [4], and surgical resection is currently the only possible curative treatment; however, even after resection, the 5-year survival rate is less than 20% due to
the high frequency of distant metastases and local recurrence [5]. The pancreas head is near the duodenum, the pancreas body tail is located behind the stomach, and the pancreas tail extends towards the splenic hilum. Islet cells are mainly distributed in the tail of the body [6]. Clinically, PHC is mostly derived from pancreatic duct epithelial cells, while PBTC is mostly derived from acinar and islet cells. Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) have been definitively indicated as precursors of pancreatic ductal adenocarcinoma [7, 8]. A study found that MCNs (as defined by ovarian-type stroma) mainly occur in female patients (>95%) and are predominantly located in the body-tail region of the pancreas (>95%) [9]. Milanetto et al. found that immunohistochemical analysis showed positivity for CK7 expression in 100% of MCNs. For operable patients, PBTC mainly performs standard pancreatic resections (distal pancreatectomy and pancreaticoduodenectomy) [10].

PBTC is relatively uncommon in clinical practice. Approximately 60–70% of PAADs are located in the head of the pancreas, and the rest, with a similar rate of approximately 15%, are located in the body and tail of the pancreas, respectively [11]. However, there are fewer cases of PBTC in clinical practice, and the prognosis and suitability of the choice of treatment remain unclear. Previous studies have shown that the prognosis of PBTC in PAAD is poor [12]. Currently, surgery is the only curable option, and radiotherapy combined with gemcitabine chemotherapy remains the main treatment for patients with advanced disease [13–15].

In the present study, we defined patients with stage III to IV PBTC as having advanced PBTC according to the AJCC-TNM 7th edition. The nomogram is a new multivariate model capable of integrating the relative contribution of each prognostic variable to the prognostic prediction outcome [16, 17]. Although the role of the nomogram has been validated in various cancers [18–20], its use in patients with advanced PBTC applications has not been adequately studied. Therefore, we retrospectively analysed 1256 advanced PBTC patients from the SEER database to establish a valuable nomogram based on a Cox proportional hazards regression model to predict 1-, 3-, and 5-year survival in advanced PBTC patients and to validate it.

**Materials and methods**

**Data extraction**

Our study used the SEER database, which is one of the more widely used and reliable publicly-available cancer databases, covering approximately 28% of the US population [21]. Clinicopathological data on advanced PBTC were collected from the SEER database (Database name = Incidence—SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000–2018)—Linked To County Attributes—Total U.S., 1969–2019 Counties) using SEER*Stat 8.3.9.2 (http://seer.cancer.gov).

We searched the SEER database for patients with a tumour location of pancreatic body tail and a primary tumour of pancreatic body tail cancer with positive histological pathology confirmation. Well-established data on age, race, tumour stage and treatment types were available, and complete and valid follow-up records were available with no missing follow-up data. The study protocol was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Since this is a retrospective study and the patient information in the SEER database is anonymous, ethical consent is not required for using these data [22, 23].

**Characteristic variables and survival data**

Patient clinicopathological data were obtained from the following datasets: age, sex, race, TNM and histological staging, whether surgery was performed, whether radiotherapy was administered, survival data, and vital status. TNM stage was manually adjusted according to the American Joint Committee on Cancer (AJCC) seventh edition criteria. To construct a Cox regression-based analysis, patients were grouped by age at diagnosis, with 65 years of age being the cut-off between groups. We included those in the radiotherapy and chemotherapy group who were unknown about radiotherapy and chemotherapy in the no radiotherapy and chemotherapy group. The primary endpoint of this analysis was OS derived from vital status and months of survival, with months of survival calculated from the day of surgery to the last follow-up or death. Patients who survived less than 1 month were coded as having zero survival time in the SEER database, and the sample with zero survival time was excluded from this study.

**Statistical analysis**

We used the χ2 test (or Fisher’s exact test) for the clinicopathological characteristics of the study population. Survival analysis was performed using Kaplan–Meier estimation and the log-rank test. For the construction of Cox proportional hazards regression models, they were first calculated using R 4.1.2 (http://www.r-project.org/) and validated using SPSS software (IBM corporation, version 22.0.0) calculations, including univariate analysis (UVA) and multivariate analysis (MVA), and hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated to assess the impact of clinical indicators on patient prognosis. A nomogram was constructed based on the MVA results. Independent prognostic factors were used to draw nomograms to predict 1-, 3-, and
5-year OS in patients with advanced PBTC. In this study, we used the training cohort to construct nomograms that were validated in the validation cohort. AUCs of ROC curves and C-indices were calculated, and calibration curves were plotted to assess the predictive power of the model. DCA was used to assess the utility of nomograms for decision-making [24]. Kaplan–Meier survival curves were plotted according to age, grade, N stage, M stage, surgery, and chemotherapy. Analyses were performed with R using the rms, Hmisc, lattice, survival, formula, ggplot2, rmda, survminer, pROC, timeROC, and foreign packages. 

\[ p \text{ values < 0.05 were considered statistically significant.} \]

## Results

### Patient clinicopathological and demographic characteristics

We performed a rigorous selection process that resulted in 1256 patients with advanced PBTC from the SEER database search. According to a 7:3 ratio, 879 patients were randomly assigned to the training cohort, and 377 patients were randomly assigned to the validation cohort using the random sampling method. The distribution of all variables was similar between the two groups and was not statistically significant (\( p > 0.05 \)). Detailed clinicopathological and demographic information is presented in Table 1. In the total sample, patients were divided into two age groups (< 65 and \( \geq 65 \) years), with 55.6% of patients aged \( \geq 65 \) years. Males accounted for 53.3%, the majority were white (\( n = 955 \)), 42% were poorly differentiated in grade III, and 81% were AJCC stage IV patients. The TNM stage was predominantly T4 (\( n = 485 \)), 61% in N0, and 81% in M1. For treatment, only 25.3% of patients underwent surgery, 12.7% underwent radiotherapy, and 65.1% underwent chemotherapy.

### Identification of prognostic factors

Univariate analysis showed that seven factors with a \( p \) value < 0.05 were closely associated with patient OS. Considering the prognostic role of N stage and chemotherapy on patients, we included them in multivariate analysis. Due to a potential correlation with TNM staging, AJCC staging was excluded from MVA to avoid covariance between factors. The results of the UVA and MVA Cox regression analysis models are shown in Table 2. Age (\( P < 0.05 \)), grade (\( P < 0.05 \)), N stage (\( P < 0.05 \)), M stage (\( P = 0.033 \)), surgery (\( P < 0.05 \)), and chemotherapy (\( P < 0.05 \)) were independent predictors of survival.

### Construction of the prognostic nomogram

We constructed a nomogram for OS based on independent prognostic factors selected using multivariate Cox analysis (Fig. 1). The nomograms showed that grade contributed the most to predicting OS in patients with advanced PBTC, followed by surgery, chemotherapy, M-stage, age, and N-stage. Each significant variable was assigned a weighted score ranging from 1 to 100. These scores were then summed to determine the value of the vertical intersection of the
probability of survival axis and the total score axis, which implies the prognosis for survival at 1, 3, and 5 years for patients with advanced PBTC.

**Nomogram validation**

In our study, the C-index, ROC curve, and calibration plots were used to assess the utility of the nomogram. In the training cohort, the C-index value was 0.709, and the AUC value of the ROC curve was 0.777 (Fig. 2A), while age, grade, N stage, M stage, surgery, and chemotherapy were 0.562, 0.621, 0.5, 0.576, 0.632 and 0.323, respectively. Meanwhile, the calibration plots of the OS nomograms showed high agreement between the nomogram predictions and actual data (Fig. 3A–C). In the validation

---

**Table 2** Univariate and multivariate cox regression model of overall survival for advanced PBTC

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|----------------------|
|           | HR                  | 95% CI               | P        | HR                  | 95% CI               | P       |
| Age       |                     |                      |         |                     |                      |         |
| < 65      | Ref                 |                      |         |                     |                      |         |
| ≥ 65      | 1.491               | 1.324–1.678          | 0.000   | 1.355               | 1.202–1.528          | 0.000   |
| Sex       |                     |                      |         |                     |                      |         |
| Male      | Ref                 |                      |         |                     |                      |         |
| Female    | 0.945               | 0.841–1.061          | 0.339   |                     |                      |         |
| Race      |                     |                      |         |                     |                      |         |
| White     | Ref                 |                      |         |                     |                      |         |
| Black     | 1.041               | 0.89–1.218           | 0.612   |                     |                      |         |
| Others    | 0.987               | 0.783–1.244          | 0.912   |                     |                      |         |
| Grade     |                     |                      |         |                     |                      |         |
| I (Well)  | Ref                 |                      |         |                     |                      |         |
| II (Moderately) | 2.328           | 1.913–2.832          | 0.000   | 2.280               | 1.863–2.790          | 0.000   |
| III (Poorly) | 3.159            | 2.597–3.844          | 0.000   | 2.854               | 2.326–3.502          | 0.000   |
| IV (Undifferentiated) | 2.379          | 1.589–3.561          | 0.000   | 2.419               | 1.610–3.636          | 0.000   |
| AJCC stage |                 |                      |         |                     |                      |         |
| III       | Ref                 |                      |         |                     |                      |         |
| IV        | 1.306               | 1.126–1.514          | 0.000   |                     |                      |         |
| T stage   |                     |                      |         |                     |                      |         |
| T1        | Ref                 |                      |         |                     |                      |         |
| T2        | 1.755               | 1.175–2.620          | 0.006   | 1.029               | 0.687–1.540          | 0.891   |
| T3        | 1.246               | 0.837–1.856          | 0.279   | 0.941               | 0.629–1.408          | 0.769   |
| T4        | 1.393               | 0.937–2.069          | 0.101   | 0.955               | 0.633–1.442          | 0.827   |
| N stage   |                     |                      |         |                     |                      |         |
| N0        | Ref                 |                      |         |                     |                      |         |
| N1        | 0.953               | 0.846–1.073          | 0.424   | 1.246               | 1.101–1.409          | 0.000   |
| M stage   |                     |                      |         |                     |                      |         |
| M0        | Ref                 |                      |         |                     |                      |         |
| M1        | 1.306               | 1.126–1.514          | 0.000   | 1.233               | 1.017–1.494          | 0.033   |
| Surgery   |                     |                      |         |                     |                      |         |
| No        | Ref                 |                      |         |                     |                      |         |
| Yes       | 0.337               | 0.290–0.391          | 0.000   | 0.350               | 0.297–0.413          | 0.000   |
| Radiotherapy |                  |                      |         |                     |                      |         |
| No        | Ref                 |                      |         |                     |                      |         |
| Yes       | 0.735               | 0.618–0.873          | 0.000   | 0.891               | 0.740–1.072          | 0.221   |
| Chemotherapy |                |                      |         |                     |                      |         |
| No        | Ref                 |                      |         |                     |                      |         |
| Yes       | 0.972               | 0.858–1.102          | 0.062   | 0.699               | 0.612–0.798          | 0.000   |

PBTC: pancreatic body tail cancer, HR: hazard ratio, CI: confidence intervals, AJCC: American joint committee on cancer.
Fig. 1 Nomogram for predicting 1-, 3-, and 5-year OS rates in patients with advanced PBTC. The points for each variable can be estimated by plotting a vertical line upwards from the patient’s variable values to the top axis marked as “points”. A vertical line is drawn downwards from the sum of all variable values on the “total points” axis to calculate 1-, 3-, and 5-year OS rates. OS: overall survival; PBTC: pancreatic body tail cancer

Fig. 2 Correlation ROC curve analysis of prognostic models for advanced PBTC. Different colours represent different curves, where red, black, green, blue, brown, orange, and purple represent the nomogram model, age, grade, N, M, surgery, and chemotherapy, respectively. A In the training cohort, the AUC values for the nomogram, age, grade, N stage, M stage, surgery and chemotherapy were 0.777, 0.562, 0.621, 0.5, 0.576, 0.632 and 0.323, respectively. B In the validation cohort, the AUC values for the nomogram, age, grade, N stage, M stage, surgery and chemotherapy were 0.772, 0.551, 0.629, 0.534, 0.577, 0.606, and 0.639, respectively. ROC: receiver operating characteristic; AUC: area under the curve; PBTC: pancreatic body tail cancer
group, the C-index value of the nomogram for predicting OS was 0.708. As shown in Fig. 2B, the AUC value was 0.772, while age, grade, N stage, M stage, surgery and chemotherapy were 0.551, 0.629, 0.534, 0.577, 0.606, and 0.639, respectively. In addition, calibration plots in the validation cohort showed satisfactory performance of the predicted and actual values (Fig. 3D–F).
Comparison of the nomogram and AJCC TNM staging systems

We compared the nomogram model with the seventh edition of the AJCC TNM staging. DCA was used to assess the utility of the new model for predicting prognosis. As shown in Fig. 4, this new model is clinically useful and has a greater net gain in predicting OS than the AJCC staging system in both the training and validation cohorts.

In addition, the cumulative survival of patients in each group is shown in Fig. 5. There was a significant difference in the likelihood of survival between the groups for patients aged < 65 and ≥ 65 years (\(P < 0.05\), Fig. 5A), which showed that patients aged ≥ 65 years had a significantly worse OS. Among the grade-stage patients, grade I had the best prognosis, and among the M-stage patients, M0 had a better prognosis than M1 (\(P < 0.05\), Fig. 5B, C). The prognosis was significantly better for patients who underwent surgery than those who did not (\(P < 0.05\), Fig. 5D). However, the effect of N stage and chemotherapy on OS was not significant (\(P > 0.05\), Fig. 5E, F).

Discussion

Pancreatic cancer is highly malignant and is currently the seventh leading cause of cancer death worldwide, ranking fourth in Europe and the United States after lung, colorectal, and breast cancer, and is expected to become the third by 2030 [25], while its publication rate is also on the rise in China [26]. Because PBTC is uncommon in pancreatic cancer, and there are few studies on advanced PBTC, its incidence increases with the total number of patients with pancreatic cancer, so we need to further study it to guide clinical treatment. Currently, the TNM staging system is usually used to predict and evaluate the prognosis of PBTC patients in clinical practice, but it has limitations because it does not consider other factors affecting survival. Therefore, we constructed a nomogram model for advanced PBTC patients to comprehensively and accurately predict survival prognosis to fill the gap in applying this model in advanced PBTC.

In this study, we analysed the clinical information related to 1256 patients diagnosed with advanced PBTC, established a prognostic model, and validated it. We found that there were more nonsurgical patients, patients undergoing radiotherapy and chemotherapy, and a higher proportion of patients with M1 stage and high T stage, but in grade stage, we found that advanced PBTC patients were predominantly intermediate and poorly differentiated, while undifferentiated accounted for the least (2.5%). Additionally, the analysis of the N stage revealed that N0 accounted for a larger proportion, while the proportion of patients with lymphatic metastases was only 39%. MORITA K et al. found that a reduction in lymphatic infiltrative metastasis was associated with adjuvant therapy such as radiotherapy and chemotherapy [27]; the exact mechanism of which has not been elucidated and may be related to the destruction of small lymphatic vessels associated with cancer and the killing of tumour cells. In addition, several studies have shown that the number of lymph node metastases and positive nodes are strongly associated with overall survival in patients with resectable pancreatic ductal adenocarcinoma [28, 29].
Fig. 5 Kaplan–Meier curves show overall survival in patients with advanced PBTC. A Kaplan–Meier curves for OS in age groups. B Kaplan–Meier curves for OS in the grade groups. C Kaplan–Meier curves for OS in the M groups. D Kaplan–Meier curves for OS in the surgery groups. E Kaplan–Meier curves for OS in the N groups. F Kaplan–Meier curves for OS in the chemotherapy groups. $P < 0.05$ was considered statistically significant. OS: overall survival; PBTC: pancreatic body tail cancer.
However, the number of regional lymph nodes retrieved and evaluated is influenced by the anatomical site of lymph nodes, the extent of debridement, and the accuracy of pathological examination [30].

Diagnostically, the overall sensitivity of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the diagnosis of pancreatic cancer is approximately 90% due to its high accuracy and low complications [31]. In clinical practice, EUS-FNA has become the most accurate method for the preoperative diagnosis of pancreatic malignancies [32]. However, a routine preoperative biopsy is generally not recommended to prevent tumour spread from needle implantation. For patients who are difficult to identify and require radiotherapy or chemotherapy, the pathological examination can be performed using a needle biopsy. For patients with PBTC without distant metastases, radical resection is the primary approach, with pancreatic body and tail resection to preserve pancreatic function. Laparoscopic surgery may be used more often in clinical practice, and some studies have found that it may have better advantages in reducing complications such as bleeding [33]. This is because excessive blood loss can cause tumour cell spread and elevated levels of interleukins 1 and 6, leading to early tumour recurrence and poorer survival rates [34, 35]. Inoperable pancreatic cancer has traditionally been treated with gemcitabine, but it is easily resistant and has poor survival rates. Failure of clinical treatment in patients with pancreatic cancer is often due to the heterogeneity of the disease [36]. In contrast, combination chemotherapy with FOLFORINOX (a combination of folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin, or a combination of gemcitabine and nab-paclitaxel) and gemcitabine is more effective than gemcitabine alone. Albumin-bound paclitaxel (nab-paclitaxel) was approved by the Food and Drug Administration (FDA) in 2013 for the treatment of pancreatic cancer in combination with gemcitabine [37]. However, in most patients with advanced disease, these treatments only prolong survival by a few months, and the combination therapy also leads to a significant increase in toxicity [38]. Targeted drugs for pancreatic cancer are also in development and exploration [36]. We identified age, grade, M-stage, and surgery as independent prognostic factors based on Cox regression and Kaplan–Meier survival analyses. In advanced PBTC, Kaplan–Meier survival analysis of N stage and chemotherapy was not statistically significant.

In our study, the nomogram was constructed based on multivariate outcomes, which need to be validated to avoid overfitting and improve generalizability [39]. The C-index and AUC values were used to assess the accuracy and discrimination of the nomogram for OS in patients with advanced PBTC [40]. Here, the C-index was 0.709 and 0.708 in the training and validation cohorts, respectively, and the AUC values were 0.777 and 0.772. Calibration curves were plotted to demonstrate the good performance of this novel model [16]. In addition, DCA was used to ensure that the nomogram was a relatively good predictor of survival time in patients with advanced PBTC.

Our study also has some limitations. First, it is a retrospective study based on the SEER database. There may be some degree of bias because the information recorded in the SEER database is incomplete. Second, information on possible important prognostic factors was incompletely recorded, such as the absence of detailed chemotherapy regimens and doses. Third, this study is a single retrospective analysis, and more prospective and multicentre studies are needed to validate the model; thus, the model will be more convincing. Finally, since the sample size for advanced PBTC is relatively small, further studies with larger sample sizes are required.

Conclusion
We constructed prediction models based on the SEER database to predict advanced PBTC, and their reliability and applicability were validated. Age, grade, M-stage, and surgery were independently associated with OS. The nomogram can be used to effectively predict 1-year, 3-year, and 5-year OS in these patients.

Abbreviations
PBTC: Pancreatic body tail cancer; OS: Overall survival; SEER: Surveillance, epidemiology, and end results; AUC: Area under the curve; ROC: Receiver operating characteristic; DCA: Decision curve analysis; PAAD: Pancreatic adenocarcinoma of the duct; AJCC: American joint committee on cancer; UVA: Univariate analysis; MVA: Multivariate analysis; HRs: Hazard ratios; 95% CIs: 95% confidence intervals; EUS-FNA: Endoscopic ultrasound-guided fine-needle aspiration; S-FU: 5-fluorouracil; nab-paclitaxel: And albumin-bound paclitaxel; FOLFORINOX: A combination of folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin, or a combination of gemcitabine and nab-paclitaxel; FDA: Food and drug administration; IPMN: Intraductal papillary mucinous neoplasms; MCN: Mucinous cystic neoplasms.

Acknowledgements
We are grateful to have the SEER database as an open platform to facilitate our data collection and analysis.

Author contributions
WZ designed the study; HS wrote the manuscript; HS, ZC, SD, RH, YD, and MCN: Mucinous cystic neoplasms. and drug administration; IPMN: Intraductal papillary mucinous neoplasms; PAAD: Pancreatic adenocarcinoma of the duct; AJCC: American joint committee on cancer; UVA: Univariate analysis; MVA: Multivariate analysis; HRs: Hazard ratios; 95% CIs: 95% confidence intervals; EUS-FNA: Endoscopic ultrasound-guided fine-needle aspiration; S-FU: 5-fluorouracil; nab-paclitaxel: And albumin-bound paclitaxel; FOLFORINOX: A combination of folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin, or a combination of gemcitabine and nab-paclitaxel; FDA: Food and drug administration; IPMN: Intraductal papillary mucinous neoplasms; MCN: Mucinous cystic neoplasms.

We are grateful to have the SEER database as an open platform to facilitate our data collection and analysis.

Author contributions
WZ designed the study; HS wrote the manuscript; HS, ZC, SD, RH, YD, and ZQ collected and analysed the data. All authors read and approved the final manuscript. We declare no potential conflict of interest, and agree to publish and sign. All authors read and approved the final manuscript.

Funding
The authors received no funding for this research.

Availability of data and materials
The data used and analysed during this study are available in an open database, the Surveillance, Epidemiology, and End Results (SEER) 18 Registries Data (https://seer.cancer.gov/).
Declarations

Ethics approval and consent to participate
Not applicable. The patient information in the SEER database is anonymous, and ethical consent was not required for using these data.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 The First Clinical Medical College, Lanzhou University, Lanzhou, China.
2 Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, China.
3 School of Stomatology, Lanzhou University, Lanzhou, China.

Received: 15 March 2022 Accepted: 30 May 2022

Published online: 03 June 2022

References

1. Chen H, Kong Y, Yao Q, Zhang X, Fu Y, Li J, Liu C, Wang Z. Three hypomethy-
lated genes were associated with poor overall survival in pancreatic cancer patients. Aging (Albany NY). 2019;11(3):885–97.

2. Li D, Xie K, Wolf R, Abbuzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57.

3. Siegel R, Nashadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

4. Hidalgo M, Cascinu S, Kleeff J, Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Panreatology. 2015;15(1):8–18.

5. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkert C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

6. Burke ZD, Tosh D. Ontogenesis of hepatic and pancreatic stem cells. Stem Cell Rev Rep. 2012;8(2):586–96.

7. Ren R, Krishna SG, Chen W, Frankel WL, Shen R, Zhao W, Avenarius MR, Gateo J, Caruthers S, Jones D. Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation. Mod Pathol. 2021;34(2):438–44.

8. Springer S, Masica DL, Dal Molin M, Douville C, Thoburn C, Alseri B, Li L, Cohen JD, Thompson E, Allen PJ, et al. A multimodality test to guide the management of patients with a pancreatic cyst. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aav4772.

9. Goh BRK, Tan Y-M, Chung Y-FA, Chou PKH, Chiew P-C, Wong W-K, Ooi LLPI. A review of mucinous cystic neoplasms of the pancreas defined by ovari-an-type stroma: clinicopathological features of 344 patients. World J Surg. 2006;30(12):2236–45.

10. Milianetto AC, Tonello AS, Valotto G, Munari G, Luchini C, Fassan M, Pas-saccini M. Simple mucinous cyst: another potential cancer precursor in the pancreas? Case report with molecular characterization and systematic review of the literature. Virchow Arch. 2017;479(1):179–89.

11. Luchini C, Capelli P, Scarpa A. Pancreatic ductal adenocarcinoma and its variants. Surg Pathol Clin. 2016;9(4):57–60.

12. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford). 2008;10(S):371–6.

13. Okada K-I, Kawai M, Hirono S, Shao M, Tani M, Matsumoto J, Yamada S, Amano R, Toyama H, Yamashita Y-I, et al. IL10 and IL18 in patients with resectable pancreatic cancer: a prospective study. J Gastroenterol. 2022;57(7):1689–97.

14. Tomioka A, Shimizu T, Kagota S, Taniguchi K, Komeda K, Asakuma M, Hirokawa F, Uchiyama K. Association between preoperative serum level of cytokeratin 19 and postoperative survival in patients with resectable pancreatic adenocarcinoma. J Gastroenterol. 2015;50(9):1082–90.

15. Schmocker RK, Delitto D, Wright MJ, Ding D, Cameron JL, Lafaro KJ, Burns WR, Wolfgang CL, Burkart RA, He J. Impact of margin status on survival in patients with pancreatic ductal adenocarcinoma receiving neoadjuvant chemoradiotherapy. J Am Coll Surg. 2021;223(4):405–13.

16. Balachandran VP, Ratan K, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.

17. Ye L, Hu C, Wang C, Yu W, Liu F, Chen Z. Nomogram for predicting the overall survival and cancer-specific survival of patients with extremely liposarcoma: a population-based study. BMC Cancer. 2020;20(1):889.

18. Ren H, Bazhin AV, Pretzsch E, Jacob S, Zhu H, Zhu J, Albertsmeier M, Lindner LH, Knösel T, Werner J, et al. A novel immune-related gene signature predicting survival in sarcoma patients. Mol Ther Oncol. 2022;24:114–26.

19. Yoshikawa T, Takenaka D, Ohtomo Y. Editorial for MRI radiomics-based nomogram from primary tumor for pretreatment prediction of peripancreatic lymph node metastasis in pancreatic ductal adenocarcinoma: a multicenter study. J Magn Reson Imagin. 2022;55(3):840–1.

20. Cheng E, Ou F-S, Ma C, Spiegelman D, Zhang Y, Zhou X, Bainter TM, Saltz LB, Niedzwiecki D, Mayer RJ, et al. Diet- and lifestyle-based prediction models to estimate cancer recurrence and death in patients with stage III colon cancer (CALGB 89803/Alice). J Clin Oncol. 2022;40(7):740–51.

21. Tao W, Fu Z, Wang K, Wu J, Xu B, Chen M. Prognostic nomogram for patients with lung metastatic renal cell carcinoma: a SEER-based study. Ann Palliat Med. 2021;10(3):2791–804.

22. Liu Z, Wu S, Li Y, Wu H, Li Y. A population-based study of the incidence and survival of anorectal gastrointestinal stromal tumor. Med Sci Monit. 2019;25:5408–17.

23. Wei J, Yang P, Huang Q, Chen Z, Zhang T, He F, Hu H, Zhong J, Li W, Wei F, et al. Proximal versus total gastrectomy for proximal gastric cancer: a surveillance, epidemiology, and end results program database analysis. Future Oncol. 2021;17(10):1185–95.

24. Van Calster B, Wynants L, Verbeek JFM, Verbakel JY, Christodoulou E, Vickers AJ, Roobol MJ, Steyerberg EW. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. 2018;74(6):796–804.

25. Tonini V, Zanini M. Pancreatic cancer in 2021: what you need to know to win. World J Gastroenterol. 2021;27(35):5851–89.

26. Cai J, Chen HD, Lu M, Zhang YH, Lu B, You L, Dai M, Zhao YP. Trend analysis on morbidity and mortality of pancreatic cancer in China, 2005–2015. Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42(5):794–800.

27. Morita K, Oshiro H, Mito K, Mieno MN, Tamba-Sakaguchi M, Niki T, Miki K, Koizumi M, Sakuma Y, Komatsubara T, et al. Prognostic significance of the degree of lymphatic vessel invasion in locally advanced, surgically resectable pancreatic head cancer: a single center experience. Medicine (Baltimore). 2018;97(49):e13466.

28. Elshaer M, Gavant E, Kossim M, Riaz A, Al-Bahnani A. A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. Ann R Coll Surg Engl. 2017;99(2):101–6.

29. Allen PJ, Kuk D, Castillo CFO, Basturk O, Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide V, He J, et al. Multi-institutional validation study of the american joint commission on cancer (8th Edition) changes for T and N staging in patients with Pancreatic adenocarcinoma. Annals Surg. 2017;265(1):185–91. https://doi.org/10.1097/SLA.0000000000001763.

30. Warschowik R, Widmann B, Beutner U, Al-Bahnani A. A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. Annals R Coll Surg Engl. 2017;99(2):101–6.

31. Kitano M, Minaga K, Hatamaru K, Ashida R. Clinical dilemma of endoscopic ultrasound-guided fine needle aspiration versus percutaneous ultrasound-guided fine needle aspiration in diagnosis of focal pancreatic masses. Endosc Ultras. 2013;24(4):190–3.

32. Wu EJ, Kabir T, Zhao JG, BKP Minimally invasive versus open radical antegrade modular pancreatosplenectomy: a meta-analysis. World J Surg. 2022;46(1):235–45.
34. Tol JAMG, Gouma DJ, Bassi C, Derenisi C, Montorsi M, Adham M, Andren-Sandberg A, Asbun HJ, Bockhorn M, Buchler MW, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the international study group on pancreatic surgery (ISGPS). Surgery. 2014;156(3):591–600.

35. Stauffer JA, Asbun HJ. Minimally invasive pancreatic surgery. Semin Oncol. 2015;42(1):123–33.

36. Matsuoka T, Yashiro M. Molecular targets for the treatment of pancreatic cancer: clinical and experimental studies. World J Gastroenterol. 2016;22(2):776–89.

37. Borazanci E, Von Hoff DD. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2014;8(7):739–47.

38. Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park). 2014;28(1):70–4.

39. Glynne-Jones R, Rao S. Treatment of the primary tumor in anal canal cancers. Surg Oncol Clin N Am. 2017;26(1):73–90.

40. Wang X, Mao M, He Z, Zhang L, Li H, Lin J, He Y, Dai S, Hu W, Liu W. Development and validation of a diagnostic nomogram in AFP-negative hepatocellular carcinoma. Int J Biostat. 2019;15(1):221–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.